Logo image of WAY

WAYSTAR HOLDING CORP (WAY) Stock Fundamental Analysis

NASDAQ:WAY - Nasdaq - US9467841055 - Common Stock - Currency: USD

35.59  -1.39 (-3.76%)

After market: 35.59 0 (0%)

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to WAY. WAY was compared to 35 industry peers in the Health Care Technology industry. Both the profitability and the financial health of WAY get a neutral evaluation. Nothing too spectacular is happening here. WAY is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year WAY was profitable.
In the past year WAY had a positive cash flow from operations.
WAY Yearly Net Income VS EBIT VS OCF VS FCFWAY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 50M -50M 100M 150M

1.2 Ratios

With an excellent Return On Assets value of 0.56%, WAY belongs to the best of the industry, outperforming 88.57% of the companies in the same industry.
WAY's Return On Equity of 0.83% is amongst the best of the industry. WAY outperforms 88.57% of its industry peers.
The Return On Invested Capital of WAY (2.71%) is better than 80.00% of its industry peers.
The Average Return On Invested Capital over the past 3 years for WAY is below the industry average of 6.51%.
The last Return On Invested Capital (2.71%) for WAY is above the 3 year average (2.09%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 0.56%
ROE 0.83%
ROIC 2.71%
ROA(3y)-0.88%
ROA(5y)N/A
ROE(3y)-1.85%
ROE(5y)N/A
ROIC(3y)2.09%
ROIC(5y)N/A
WAY Yearly ROA, ROE, ROICWAY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 1 -1 2 -2

1.3 Margins

WAY has a Profit Margin of 2.67%. This is amongst the best in the industry. WAY outperforms 88.57% of its industry peers.
Looking at the Operating Margin, with a value of 15.77%, WAY belongs to the top of the industry, outperforming 94.29% of the companies in the same industry.
WAY's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 66.79%, WAY is in the better half of the industry, outperforming 68.57% of the companies in the same industry.
In the last couple of years the Gross Margin of WAY has declined.
Industry RankSector Rank
OM 15.77%
PM (TTM) 2.67%
GM 66.79%
OM growth 3Y7.95%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5YN/A
WAY Yearly Profit, Operating, Gross MarginsWAY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 20 40 60

More info and screens

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so WAY is destroying value.
The number of shares outstanding for WAY has been increased compared to 1 year ago.
WAY has a better debt/assets ratio than last year.
WAY Yearly Shares OutstandingWAY Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 50M 100M 150M
WAY Yearly Total Debt VS Total AssetsWAY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

An Altman-Z score of 2.93 indicates that WAY is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.93, WAY is in the better half of the industry, outperforming 74.29% of the companies in the same industry.
WAY has a debt to FCF ratio of 6.33. This is a slightly negative value and a sign of low solvency as WAY would need 6.33 years to pay back of all of its debts.
With a Debt to FCF ratio value of 6.33, WAY perfoms like the industry average, outperforming 57.14% of the companies in the same industry.
A Debt/Equity ratio of 0.39 indicates that WAY is not too dependend on debt financing.
WAY has a Debt to Equity ratio of 0.39. This is in the lower half of the industry: WAY underperforms 62.86% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF 6.33
Altman-Z 2.93
ROIC/WACC0.29
WACC9.43%
WAY Yearly LT Debt VS Equity VS FCFWAY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 1B 2B 3B

2.3 Liquidity

WAY has a Current Ratio of 3.12. This indicates that WAY is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.12, WAY is in the better half of the industry, outperforming 77.14% of the companies in the same industry.
WAY has a Quick Ratio of 3.12. This indicates that WAY is financially healthy and has no problem in meeting its short term obligations.
WAY has a Quick ratio of 3.12. This is in the better half of the industry: WAY outperforms 77.14% of its industry peers.
Industry RankSector Rank
Current Ratio 3.12
Quick Ratio 3.12
WAY Yearly Current Assets VS Current LiabilitesWAY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

WAY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.57%, which is quite impressive.
Looking at the last year, WAY shows a quite strong growth in Revenue. The Revenue has grown by 19.28% in the last year.
WAY shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.71% yearly.
EPS 1Y (TTM)58.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%269.46%
Revenue 1Y (TTM)19.28%
Revenue growth 3Y17.71%
Revenue growth 5YN/A
Sales Q2Q%14.08%

3.2 Future

The Earnings Per Share is expected to grow by 76.92% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 10.10% on average over the next years. This is quite good.
EPS Next Y323.93%
EPS Next 2Y118.74%
EPS Next 3Y76.92%
EPS Next 5YN/A
Revenue Next Year9.88%
Revenue Next 2Y9.63%
Revenue Next 3Y10.1%
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
WAY Yearly Revenue VS EstimatesWAY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M 1B
WAY Yearly EPS VS EstimatesWAY Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 0.5 1 1.5

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

WAY is valuated quite expensively with a Price/Earnings ratio of 45.05.
71.43% of the companies in the same industry are more expensive than WAY, based on the Price/Earnings ratio.
WAY's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.82.
Based on the Price/Forward Earnings ratio of 23.45, the valuation of WAY can be described as rather expensive.
74.29% of the companies in the same industry are more expensive than WAY, based on the Price/Forward Earnings ratio.
WAY is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 36.21, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 45.05
Fwd PE 23.45
WAY Price Earnings VS Forward Price EarningsWAY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, WAY is valued a bit cheaper than 71.43% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, WAY is valued a bit cheaper than 74.29% of the companies in the same industry.
Industry RankSector Rank
P/FCF 31.61
EV/EBITDA 22.49
WAY Per share dataWAY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
WAY has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as WAY's earnings are expected to grow with 76.92% in the coming years.
PEG (NY)0.14
PEG (5Y)N/A
EPS Next 2Y118.74%
EPS Next 3Y76.92%

More info and screens

0

5. Dividend

5.1 Amount

WAY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

WAYSTAR HOLDING CORP

NASDAQ:WAY (8/1/2025, 8:10:30 PM)

After market: 35.59 0 (0%)

35.59

-1.39 (-3.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)07-30 2025-07-30/amc
Earnings (Next)11-04 2025-11-04
Inst Owners64.6%
Inst Owner Change0.06%
Ins Owners1.33%
Ins Owner Change5.81%
Market Cap6.20B
Analysts85.26
Price Target49.13 (38.04%)
Short Float %4.16%
Short Ratio2.78
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)51.34%
Min EPS beat(2)-1.27%
Max EPS beat(2)103.96%
EPS beat(4)3
Avg EPS beat(4)113.84%
Min EPS beat(4)-1.27%
Max EPS beat(4)322.74%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)3.24%
Min Revenue beat(2)2.36%
Max Revenue beat(2)4.13%
Revenue beat(4)4
Avg Revenue beat(4)5.04%
Min Revenue beat(4)2.36%
Max Revenue beat(4)7.44%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.69%
PT rev (3m)-0.48%
EPS NQ rev (1m)1.21%
EPS NQ rev (3m)2.77%
EPS NY rev (1m)0.17%
EPS NY rev (3m)1.23%
Revenue NQ rev (1m)0.02%
Revenue NQ rev (3m)1.27%
Revenue NY rev (1m)0.1%
Revenue NY rev (3m)0.78%
Valuation
Industry RankSector Rank
PE 45.05
Fwd PE 23.45
P/S 6.36
P/FCF 31.61
P/OCF 27.77
P/B 1.98
P/tB N/A
EV/EBITDA 22.49
EPS(TTM)0.79
EY2.22%
EPS(NY)1.52
Fwd EY4.26%
FCF(TTM)1.13
FCFY3.16%
OCF(TTM)1.28
OCFY3.6%
SpS5.6
BVpS17.94
TBVpS-5.19
PEG (NY)0.14
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.56%
ROE 0.83%
ROCE 3.43%
ROIC 2.71%
ROICexc 2.87%
ROICexgc 61.18%
OM 15.77%
PM (TTM) 2.67%
GM 66.79%
FCFM 20.11%
ROA(3y)-0.88%
ROA(5y)N/A
ROE(3y)-1.85%
ROE(5y)N/A
ROIC(3y)2.09%
ROIC(5y)N/A
ROICexc(3y)2.13%
ROICexc(5y)N/A
ROICexgc(3y)47.51%
ROICexgc(5y)N/A
ROCE(3y)2.64%
ROCE(5y)N/A
ROICexcg growth 3Y7.56%
ROICexcg growth 5YN/A
ROICexc growth 3Y30.65%
ROICexc growth 5YN/A
OM growth 3Y7.95%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5YN/A
F-Score7
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF 6.33
Debt/EBITDA 3.73
Cap/Depr 15.43%
Cap/Sales 2.78%
Interest Coverage 250
Cash Conversion 67.75%
Profit Quality 752.24%
Current Ratio 3.12
Quick Ratio 3.12
Altman-Z 2.93
F-Score7
WACC9.43%
ROIC/WACC0.29
Cap/Depr(3y)12.11%
Cap/Depr(5y)N/A
Cap/Sales(3y)2.69%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%269.46%
EPS Next Y323.93%
EPS Next 2Y118.74%
EPS Next 3Y76.92%
EPS Next 5YN/A
Revenue 1Y (TTM)19.28%
Revenue growth 3Y17.71%
Revenue growth 5YN/A
Sales Q2Q%14.08%
Revenue Next Year9.88%
Revenue Next 2Y9.63%
Revenue Next 3Y10.1%
Revenue Next 5YN/A
EBIT growth 1Y-12.92%
EBIT growth 3Y27.06%
EBIT growth 5YN/A
EBIT Next Year127.15%
EBIT Next 3Y40.45%
EBIT Next 5YN/A
FCF growth 1Y375.9%
FCF growth 3Y15.76%
FCF growth 5YN/A
OCF growth 1Y229.9%
OCF growth 3Y16.85%
OCF growth 5YN/A